Latest Insider Transactions at Gilead Sciences, Inc. (GILD)
This section provides a real-time view of insider transactions for Gilead Sciences, Inc. (GILD). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of GILEAD SCIENCES, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of GILEAD SCIENCES, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 03
2023
|
Anthony Welters Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,887
+19.24%
|
-
|
|
May 01
2023
|
Kevin E Lofton Director |
SELL
Bona fide gift
|
Indirect |
12,868
-12.42%
|
-
|
|
Mar 13
2023
|
Merdad Parsey Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,126
-8.03%
|
$477,828
$78.99 P/Share
|
|
Mar 10
2023
|
Daniel Patrick O'Day Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
14,017
-3.6%
|
$1,107,343
$79.5 P/Share
|
|
Mar 10
2023
|
Daniel Patrick O'Day Chairman & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,288
+3.79%
|
-
|
|
Mar 10
2023
|
Merdad Parsey Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,328
-6.53%
|
$420,912
$79.5 P/Share
|
|
Mar 10
2023
|
Merdad Parsey Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,454
+6.71%
|
-
|
|
Mar 10
2023
|
Sandra Patterson SVP, Controllership |
SELL
Payment of exercise price or tax liability
|
Direct |
801
-2.97%
|
$63,279
$79.5 P/Share
|
|
Mar 10
2023
|
Sandra Patterson SVP, Controllership |
BUY
Exercise of conversion of derivative security
|
Direct |
2,921
+5.26%
|
-
|
|
Mar 10
2023
|
Johanna Mercier Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,116
-5.86%
|
$404,164
$79.5 P/Share
|
|
Mar 10
2023
|
Johanna Mercier Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,976
+6.01%
|
-
|
|
Mar 10
2023
|
Andrew D Dickinson Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,849
-4.18%
|
$383,071
$79.5 P/Share
|
|
Mar 10
2023
|
Andrew D Dickinson Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,419
+4.35%
|
-
|
|
Mar 09
2023
|
Kevin E Lofton Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,442
+50.0%
|
$438,984
$52.38 P/Share
|
|
Mar 01
2023
|
Merdad Parsey Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,984
-15.62%
|
$1,025,736
$79.96 P/Share
|
|
Mar 01
2023
|
Daniel Patrick O'Day Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,842
-1.33%
|
$382,518
$79.59 P/Share
|
|
Mar 01
2023
|
Daniel Patrick O'Day Chairman & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,362
+3.02%
|
-
|
|
Feb 15
2023
|
Andrew D Dickinson Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
376
+0.35%
|
$21,056
$56.38 P/Share
|
|
Feb 15
2023
|
Merdad Parsey Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
376
+0.45%
|
$21,056
$56.38 P/Share
|
|
Feb 15
2023
|
Deborah H Telman EVP, Corporate Affairs & GC |
BUY
Grant, award, or other acquisition
|
Direct |
376
+50.0%
|
$21,056
$56.38 P/Share
|
|
Feb 06
2023
|
Diane E. Wilfong SVP, Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
565
-1.73%
|
$48,590
$86.36 P/Share
|
|
Feb 06
2023
|
Diane E. Wilfong SVP, Controller & CAO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,864
+5.41%
|
-
|
|
Feb 06
2023
|
Andrew D Dickinson Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
531
-0.5%
|
$45,666
$86.36 P/Share
|
|
Feb 06
2023
|
Andrew D Dickinson Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,817
+1.69%
|
-
|
|
Jan 24
2023
|
Andrew D Dickinson Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
15,327
-12.85%
|
$1,287,468
$84.02 P/Share
|
|
Jan 24
2023
|
Andrew D Dickinson Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
66,202
+24.96%
|
-
|
|
Jan 24
2023
|
Daniel Patrick O'Day Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
59,078
-14.34%
|
$4,962,552
$84.02 P/Share
|
|
Jan 24
2023
|
Daniel Patrick O'Day Chairman & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
215,017
+23.53%
|
-
|
|
Jan 24
2023
|
Johanna Mercier Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
15,325
-16.71%
|
$1,287,300
$84.02 P/Share
|
|
Jan 24
2023
|
Johanna Mercier Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
67,394
+32.37%
|
-
|
|
Jan 24
2023
|
Merdad Parsey Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
17,749
-17.66%
|
$1,490,916
$84.02 P/Share
|
|
Jan 24
2023
|
Merdad Parsey Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
73,359
+32.31%
|
-
|
|
Jan 24
2023
|
Diane E. Wilfong SVP, Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,244
-3.89%
|
$104,496
$84.02 P/Share
|
|
Jan 24
2023
|
Diane E. Wilfong SVP, Controller & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
5,884
+8.7%
|
-
|
|
Dec 30
2022
|
Merdad Parsey Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
553
-1.2%
|
$47,005
$85.33 P/Share
|
|
Dec 10
2022
|
Andrew D Dickinson Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
480
-0.69%
|
$41,760
$87.97 P/Share
|
|
Dec 10
2022
|
Andrew D Dickinson Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,027
+1.45%
|
-
|
|
Dec 10
2022
|
Johanna Mercier Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
463
-1.13%
|
$40,281
$87.97 P/Share
|
|
Dec 10
2022
|
Johanna Mercier Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
990
+2.36%
|
-
|
|
Dec 10
2022
|
Daniel Patrick O'Day Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,542
-0.6%
|
$134,154
$87.97 P/Share
|
|
Dec 10
2022
|
Daniel Patrick O'Day Chairman & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,300
+1.27%
|
-
|
|
Dec 10
2022
|
Merdad Parsey Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
486
-1.04%
|
$42,282
$87.97 P/Share
|
|
Dec 10
2022
|
Merdad Parsey Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,039
+2.18%
|
-
|
|
Dec 10
2022
|
Diane E. Wilfong SVP, Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
149
-0.52%
|
$12,963
$87.97 P/Share
|
|
Dec 10
2022
|
Diane E. Wilfong SVP, Controller & CAO |
BUY
Exercise of conversion of derivative security
|
Direct |
318
+1.1%
|
-
|
|
Nov 10
2022
|
Merdad Parsey Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,268
-4.74%
|
$185,976
$82.6 P/Share
|
|
Nov 10
2022
|
Merdad Parsey Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,099
+9.63%
|
-
|
|
Nov 10
2022
|
Andrew D Dickinson Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
851
-1.22%
|
$69,782
$82.6 P/Share
|
|
Nov 10
2022
|
Andrew D Dickinson Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,912
+2.68%
|
-
|
|
Nov 09
2022
|
Diane E. Wilfong SVP, Controller & CAO |
SELL
Open market or private sale
|
Direct |
6,416
-18.46%
|
$532,528
$83.5 P/Share
|